Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2007

View Archived Issues

Identification and preclinical characterization of a novel EGFR/SRC inhibitor SI-35

Peglyation increases and prolongs systemic exposure of irinotecan and its active metabolite in rats

Anticancer efficacy of ZK-EPO in preclinical ovarian cancer models and in patients with NSCLC

Recent patents describe new treatment options for cardiovascular diseases

New therapeutic options for cancer imparted in recent patent literature

deCODE launches clinical phase IIa trial of DG-051 in heart attack prevention

Bellicum receives Emerging Technology Fund award from the state of Texas

Adventrx completes enrollment in ANX-530 marketing-enabling study

Swissmedic to review ceftobiprole MAA for tissue infection, phase III results in HAP

Dara BioSciences and Point Therapeutics announce merger

DSMB gives positive recommendation for VIA-2291 trials

Promising preclinical data reported by Brainstorm for ALS therapy / News in Context

New orally active PAR-1 agonist described at Schering-Plough

Potent innate immune responses triggered by novel cationic lipid DNA complex adjuvant

Pooled trial data show agomelatine to be effective in severe depression

OXI-4503 well tolerated in ongoing phase I study

SLx-4090 lowers postprandial triglycerides, LDL-cholesterol in healthy men

Pharmexa reports update on GV-1001 clinical development

MK-0859 improves LDL- and HDL-cholesterol in large dyslipidemia study

Synergy seen with SQ-109 and rifampin against Mycobacterium tuberculosis

KP-1461 safe and well tolerated in phase I study in HIV patients

Dey launches Perforomist inhalation solution for long-term treatment of COPD

Recent Gruenenthal patents report novel analgesic agents

GlaxoSmithKline and Synta collaborate for STA-4783 in oncology

National Cancer Institute awards SBIR contract to Rules-Based Medicine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...